Ghassan Abou-Alfa, MD, MBA, explains the shortcomings of the RECIST study in measuring efficacy in hepatocellular carcinoma (HCC) patients at Annual Meeting 2018.
The shortcomings of the RECIST study in HCC
Ghassan Abou-Alfa, MD, MBA, explains the shortcomings of the RECIST study in measuring efficacy in hepatocellular carcinoma (HCC) patients at Annual Meeting 2018.